

Hippocrates Ventures

A Social Impact Digital Health Micro-
Venture Capital Fund for Physician
Investors

Important Information

This presentation is being provided to certain selected qualified prospective investors on a confidential basis for informational and discussion purposes only and may not be relied upon in any manner as a legal, tax or investment advice or as an offer to sell or a solicitation of an offer to buy an interest in the investment fund described herein (the "Fund"). A private offering of limited partnership interests in the Fund will only be made pursuant to a confidential offering memorandum, a limited partnership agreement and subscription documents related thereto, and subject to the terms and conditions contained in such documents and in such Fund's operative agreements, which will be furnished to qualified investors on a confidential basis. The interests in the Fund have not been, nor will they be, registered under the U.S. Securities Act of 1933, as amended, or qualified or registered under any applicable state, local, or other statutes, rules or regulations.

This presentation (as amended or supplemented in writing from time to time), is provided on a confidential basis solely for the information of those persons to whom it is provided and their professional advisers so that they may consider an investment in the limited partnership interests in the Fund, and is not to be reproduced or used for any other purpose. This presentation and the information contained herein may not be reproduced or distributed nor may its contents be disclosed to persons not directly involved with the prospective investor's decision regarding the purchase of the offered securities without the prior written consent of Hippocrates Ventures.

This presentation provides an overview of Hippocrates Ventures and is not intended to be taken by, and should not be taken by, any individual recipient as investment advice, a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security. The confidential offering memorandum relating to any Fund contains additional information about the investment objective, terms and conditions of such Fund, tax information and risk disclosure that should be reviewed prior to making an investment decision regarding a Fund. This presentation is qualified in its entirety by such confidential offering memorandum, which should be read completely before making any investment. An investment in a Fund would be speculative and would involve significant risks.

Although the information presented in this presentation has been obtained from sources that Hippocrates Ventures believes to be reliable and Hippocrates Ventures makes no representations as to its accuracy, validity, timeliness or completeness for any purpose. The information set forth herein does not purport to be complete and Hippocrates Ventures is not responsible for errors and/or omissions with respect to the information contained herein. Unless otherwise expressly stated herein any analysis or outlook relating to the matters discussed herein express Hippocrates Ventures' views only as of March [●], 2018.

Statements contained in this presentation that are not historical facts are based on current expectations, estimates, projections, opinions and/or beliefs of Hippocrates Ventures. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. Certain information contained in this presentation constitutes "forward-looking statements," which can be identified by the use of forward-looking terminology such as "may," "will," "should," "seek," "expect," "anticipate," "forecast," "project," "estimate," "intend," "continue," "target," or "believe" or the negatives thereof or other variations thereon or comparable terminology. These statements are subject to risks, uncertainties and assumptions, including those described under the section entitled "Risk Factors" in any confidential offering memorandum, as such factors may be updated from time to time. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in any confidential offering memorandum. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by applicable law.

The Problem With Healthcare Venture Capital

- Traditional VC funds are investing at later stages and missing out on high quality healthcare investments at Seed and Series A
- Traditional VC funds often lack the medical and scientific expertise necessary to properly advise and help healthcare entrepreneurs
- Traditional VCs are not interested in social impact, but most healthcare entrepreneurs are.
- Traditional venture capital funds are impatient with entrepreneurs and are quick to fire founders.
- Traditional VCs lack the social consciousness and ethics required to make a long term social impact in healthcare.
- Traditional VCs have been more focused on treating disease and have failed to recognize the opportunity to prevent chronic disease.

Healthcare entrepreneurs are frustrated with traditional venture capital funds

The Solution - Hippocrates Ventures

- Hippocrates Ventures is the world's first social impact digital health Micro-VC fund which is completely funded by physician investors. Imagine a venture capital fund with 100 physicians investing an average of \$100,000 each to create a \$10 million fund. Our physician investors will also be part of our medical think tank to help us make decisions about what companies to invest in and to help our portfolio companies succeed after we invest. Simply put, Hippocrates Ventures is a group of physicians and entrepreneurs pooling financial and intellectual capital to have a social impact on millions of patients in healthcare through the companies which we collectively invest in and nurture.

What Strategic Advantages Does Hippocrates Ventures Have Over Traditional VC Funds?


- Deal Flow - Our physician LPs will share potential investments with the fund.
- Due Diligence - Our physician LPs will help us vet potential investments from the perspective as a physician.
- Product Testing - Our physician LPs in some cases may be able to beta test the products that we invest in
- Introductions - Our physician LPs will collaborate with our portfolio companies and make helpful introductions to potential customers or partners
- Social Impact Branding - Healthcare entrepreneurs prefer physician investors over VCs due to the desire of physicians to have a social impact. Therefore, we will be able to compete with leading VCs to invest in the most promising startups.

Hippocrates Ventures Fund Structure

Fund Size	\$10 million
Carry	20% to GP
Management Fee	Up to \$300,000 / year Years 1-5
Maximum Number of Physician Investors	100
Minimum LP Investment	\$50,000
401K/IRA Investments Allowed	Yes
Fund Length	10 Years with 3 1-year optional extensions
Return on Investment Timeline	Deal-by-deal carry with loss carryforward


What Is a Micro-VC Fund?

- Micro-VC funds commonly invest in the



Digital Health Funding Snapshot - \$9BN/Year

Hippocrates Ventures provides physicians with the opportunity to impact the billions of venture capital dollars being invested into digital health each year.



What Will Hippocrates Ventures Invest In?

“Digital therapeutics”, also known as “software as a drug”, is the concept of a digital program having a clinical and repeatable outcome to either prevent or treat disease. Digital therapeutics has the potential to prevent and treat major conditions such as diabetes, heart disease, obesity, smoking cessation, alcoholism, stroke, cancer prevention, stress, mental health conditions, and a variety of other diseases. The global digital therapeutics market is anticipated to reach USD 9.4 billion by 2025, according to a new report by Grand View Research, Inc. The growth of the market is catapulted by increasing incidences of chronic diseases, increasing emphasis on preventive healthcare, the need to curb healthcare expenditures, and added benefits offered by digital therapeutics. Rise in number of venture capitalists that are investing in the market is another factor that is accelerating its growth.

(Source: The ["Digital Therapeutics Market, 2014-2025"](#) report)

In addition to software enabled healthcare services such as digital therapeutics, Hippocrates Ventures may invest in medical devices that have strong software components and have tremendous potential to improve public health

What Stage Will Hippocrates Invest In?

- Hippocrates Ventures will seek to primarily invest in startups that have reached the following stage:
 - Minimum viable product developed
 - Generating \$10K-\$50K/month of revenue (unless medical device seeking FDA-approval)
 - Clear potential business models
 - Reimbursement pathways identified or achieved if applicable
 - Products that have demonstrated a clear clinical benefit or may do so in the near future
 - Potential to improve health for millions of patients
 - Founders with a clear social mission who have made their startup their life's work

Managing Director - Laurence Girard




Laurence Girard is a serial healthcare entrepreneur and the CEO and Founder of Fruit Street. Laurence has raised over \$10 million in capital from 225 physician investors for Fruit Street. Fruit Street delivers the CDC's Diabetes Prevention Program to commercial health plans and employers through its partnership and is a fully reimbursed digital therapeutic. Laurence is an alumni of the Kairos Society and his startup Fruit Street is also a member of Startup Health. Laurence was introduced to entrepreneurship and venture capital while in the Bachelor's Degree Program at the Harvard Extension School. He spent significant time at the Harvard Innovation Lab - the entrepreneurship center of Harvard University on the Harvard Business School campus. Laurence has demonstrated his ability to lead a group of physician entrepreneurs to have a positive impact in healthcare.

Hippocrates Ventures & Social Impact

- Hippocrates Ventures is not simply a group of physicians investing, but it is a group of physicians who want to have a social impact. For this reason, Hippocrates Ventures will become a Certified B Corporation with B Corp Labs.
- B Lab is a nonprofit organization that serves a global movement of people using business as a force for good™. Its vision is that one day all companies compete not only to be the best in the world, but the Best for the World® and as a result society will enjoy a more shared and durable prosperity. B Lab drives this systemic change by:
 - 1) Building a global community of **Certified B Corporations™** who meet the highest standards of verified, overall social and environmental performance, public transparency, and legal accountability;
 - 2) Promoting **Mission Alignment** using innovative corporate structures like the benefit corporation to align the interests of business with those of society and to help high impact businesses be built to last;

Hippocrates Ventures Will Use Moonshot Thinking

When JFK said we will go to the moon, he did not know how we will get there. We believe to change healthcare, this same moonshot thinking is required as described in the following inspirational video:



Contact Us - Thank You!

Laurence Girard

laurence@hippocratesventures.com

617-981-0920